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Fibrin independent proinflammatory effects of tissue factor in
experimental crescentic glomerulonephritis.
Background. Tissue factor initiated glomerular fibrin depo-
sition is an important mediator of injury in crescentic glomeru-
lonephritis. Recent data have suggested noncoagulant roles for
tissue factor in inflammation.
Methods. To test the hypothesis that in addition to its ef-
fects in initiating coagulation, tissue factor has proinflamma-
tory effects in glomerulonephritis, rabbits given crescentic anti-
glomerular basement membrane (GBM) antibody–induced
glomerulonephritis were defibrinogenated with ancrod. One
group of defibrinogenated rabbits was also given anti-tissue fac-
tor antibodies. Comparisons were made between these groups,
as well as a third group that was neither defibrinogenated with
ancrod nor given anti-tissue factor antibodies.
Results. Defibrinogenation alone abolished glomerular fibrin
deposition, reduced crescent formation, and limited renal im-
pairment (ancrod-treated, serum creatinine 274 ± 37 lmol/L;
untreated 415 ± 51 lmol/L; P < 0.01). Tissue factor inhibi-
tion in defibrinogenated rabbits resulted in further protection
of renal function (creatinine 140 ± 19 lmol/L, P < 0.01) and re-
duced proteinuria (0.4 ± 0.2g/day, untreated 2.6 ± 0.4 g/day, P <
0.01), which was significantly increased by defibrinogenation
alone (ancrod-treated, 5.6 ± 1.2 g/day). Anti-tissue factor anti-
bodies (but not defibrinogenation alone) attenuated glomerular
T-cell and macrophage recruitment, and major histocompatibil-
ity complex (MHC) class II expression.
Conclusion. These results demonstrate important proinflam-
matory effects of tissue factor in crescentic glomerulonephritis
that are fibrin independent and provide in vivo evidence for
tissue factor’s proinflammatory effects on MHC class II expres-
sion and leukocyte accumulation.
In human crescentic glomerulonephritis, rapid and of-
ten irreversible loss of renal function is strongly associ-
ated with prominent glomerular fibrin deposition [1–4].
The association of glomerular fibrin deposition with
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an influx of T cells and macrophages together with
up-regulation of tissue factor expression in crescentic
glomerulonephritis suggests fibrin deposition may oc-
cur as part of an immune delayed-type hypersensitiv-
ity response [3, 4]. Studies using ancrod, a snake venom
extract which converts fibrinogen to a soluble fibrin
monomer which is rapidly depleted from the circulation,
have demonstrated that fibrin is an important mediator
of injury in human [5] and experimental [6–9] crescentic
glomerulonephritis.
Tissue factor initiates the extrinsic coagulation path-
way by binding circulating factor VII and facilitating its
allosteric conversion to factor VIIa [10–12]. Recent stud-
ies suggests that tissue factor may also contribute directly
to the inflammatory injury in crescentic glomerulonephri-
tis by augmenting macrophage activation and T-cell pro-
liferation, effects which appear to be mediated through
its intracytoplasmic tail [13]. The important role of tis-
sue factor in glomerular coagulation and crescent forma-
tion has recently been confirmed by experimental studies
showing that specific inhibition of tissue factor functional
activity by either antibody inhibition [14] or infusion of
the natural biologic inhibitor of tissue factor, tissue factor
pathway inhibitor (TFPI) [15], results in signifi-
cant attenuation of the development of crescentic
glomerulonephritis. Inhibition of tissue factor decreased
crescent formation, preserved renal function, and re-
duced proteinuria. In addition, tissue factor inhibition
was associated with decreased glomerular inflamma-
tion [macrophage influx and major histocompatibility
complex (MHC) class II expression]. The confounding
problem in this model (and in disseminated intravascu-
lar coagulation where tissue factor blockade has also been
shown to be protective [16]) is that coagulation and fibrin
deposition are also significantly inhibited. It is therefore
possible that the beneficial effects seen were entirely due
to inhibition of the known procoagulant effects of tissue
factor, thus preventing the injurious fibrin deposition and
the generation of factors such as factor Xa and thrombin
which have demonstrated proinflammatory effects [17–
19].
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Fibrin deposition is an end result of pathologic coagula-
tion. Fibrin is strongly associated with experimental cres-
centic glomerulonephritis [20, 21], is deposited early in,
and is critical to disease progression [8]. Experimentally,
defibrinogenation with ancrod from the commencement
of injury [6–8] or the prevention of further fibrin deposi-
tion or removal of deposited fibrin (with ancrod or strep-
tokinase) in established disease [9] decreased impairment
of renal filtration and crescent formation. However, many
parameters of cellular inflammation were unaffected and
proteinuria was significantly exacerbated. There was no
reduction in glomerular influx of macrophages. Taken to-
gether, these data confirm a key role for pathologic fib-
rin deposition in the formation of glomerular crescents
and the development of renal failure due to reduction
in glomerular filtration. However, preservation of filtra-
tion and continued macrophage-associated glomerular
inflammation lead to increased pathologic proteinuria
and continued cellular proliferation. These ongoing
pathologic events may be contributed to by the contin-
ued proinflammatory effects of augmented tissue factor
activity in the absence of fibrin deposition.
Previously various anticoagulant strategies in human
crescentic glomerulonephritis have been studied, notably
heparin, warfarin, and ancrod [5]. Despite initial enthu-
siasm, the clinical benefits in human disease have overall
been disappointing [22, 23]. Tissue factor is best known
for its procoagulant role but its proinflammatory effects
are increasingly recognized [16, 24]. Inhibition of tissue
factor may have particular benefits in situations where
both inflammation and pathologic fibrin deposition con-
tribute to injury as in crescentic glomerulonephritis. Thus
it is important to dissect the relative procoagulant from
proinflammatory effects of tissue factor in crescentic
glomerulonephritis. In order to study the role of tissue
factor receptor–mediated inflammatory effects indepen-
dent of procoagulant/fibrin-mediated effects, the current
study assessed the effects of the inhibition of tissue factor
in rabbits developing crescentic anti-glomerular base-
ment membrane (GBM) glomerulonephritis simultane-
ously defibrinogenated by the use of ancrod.
METHODS
Experimental design
Experimental accelerated autologous anti-GBM anti-
body initiated glomerulonephritis was induced in male
New Zealand White rabbits, 1.9 to 2.3 kg body weight
(Monash University Central Animal Services, Clayton,
Victoria, Australia). Infusions were given via plastic can-
nulas inserted into the right external jugular vein under
(ketamine/xylazine) anesthetic. Rabbits were bled daily
via the catheters to allow estimation of serum creati-
nine, the clot quality test and fibrinogen levels. Autol-
ogous phase anti-GBM glomerulonephritis was initiated
by the injection of horse antirabbit GBM serum as a sin-
gle intravenous bolus dose of 25 mg/kg at day 0 to rabbits
sensitized by subcutaneous injection 5 days previously
with 4 mg of normal horse globulin in 1 mL Freund’s
complete adjuvant (Sigma, Castle Hill, NSW, Australia).
The following groups of rabbits with glomerulonephri-
tis were studied: (1) control treatment (N = 5) on rab-
bits with glomerulonephritis that received saline (vehicle
for ancrod) and normal sheep globulin (control for anti-
tissue factor antibodies); (2) ancrod treatment alone (N =
5) on rabbits with glomerulonephritis that were defib-
rinogenated with ancrod and also received normal sheep
globulin (control for anti-tissue factor antibodies); and
(3) ancrod treatment and anti-tissue factor antibodies
treatment (N = 5) on rabbits with glomerulonephritis
that were both defibrinogenated with ancrod and also re-
ceived anti-tissue factor antibodies.
Twenty-four hours prior to the injection of anti-GBM
globulin, sensitized rabbits in groups 2 and 3 were
treated intravenously with ancrod (Knoll, Ludigshafen,
Germany) dissolved immediately before use (5 mL 0.9%
saline). The initial dose of 0.5 U/kg (over 60 minutes) was
followed immediately by a 2-hour infusion of 1.5 U/kg.
Further doses were given 12 hourly (2 U/kg) as a slow in-
travenous infusion. The dose of ancrod was adjusted daily
when required to keep the clot quality test of Reid, Chan,
and Thean [25] at 0 or 1. Sheep antirabbit tissue factor
antibodies were prepared according to a previously pub-
lished method [14]. Daily intravenous bolus injections
of functionally inhibitory sheep antirabbit tissue factor
antibodies (50 mg/kg) were commenced 2 hours after
the induction of glomerulonephritis (group 2). Rabbits in
groups 1 and 3 received normal sheep globulin, 50 mg/kg
intravenously daily. Four days after initiation of anti-
GBM glomerulonephritis rabbits were sacrificed. At the
time of sacrifice, no rabbit displayed any evidence of in-
ternal or external hemorrhage.
Routine hematologic parameters of platelet and
white blood cell count and hemoglobin concentrations
were assessed on blood [ethylenediaminetetraacetic acid
(EDTA) as anticoagulant] on a Coulter STKS analyzer
(Coulter Electronics, Miami, FL, USA). Measurements
of the activated partial thromboplastin time (aPTT), pro-
thrombin time (PT), and plasma fibrinogen concentra-
tions were performed on citrated blood specimens using
an Electra 1000C automatic coagulation time apparatus
(Medical Laboratory Automation Inc., Pleasantville, NY,
USA). The clot quality test of Reid, Chan, and Thean
[25] was performed once daily on nondiluted blood aspi-
rated from the jugular line. Results are expressed as the
mean ± SEM and the significance of differences between
groups were analyzed by analysis of variance (ANOVA),
followed by the Neuman-Keuls post hoc test.
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Table 1. Blood counts and coagulation parameters in rabbits used in these studies
Control Ancrod and
Normal glomerulonephritis Ancrod anti-tissue factor
Hemoglobin g/L 12.3 ± 1.8 11.6 ± 2.4 12.8 ± 2.7 11.5 ± 2.1
White cell count × 109/L 5.6 ± 1.2 6.4 ± 2.6 7.1 ± 1.4 5.9 ± 0.9
Platelets × 109/L 320 ± 21 402 ± 78 289 ± 80 334 ± 43
Fibrinogen lmol/L 2.23 ± 0.40 2.96 ± 0.39 0.20 ± 0.13 0.16 ± 0.10
aPTT seconds 16.8 ± 1.8 19.5 ± 1.4 NCD NCD
PT seconds 0.9 ± 0.1 0.9 ± 0.2 NCD NCD
Abbreviations: aPTT, activated partial thromboplastin time; PT, prothrombin time; NCD, no clot detected.
Ancrod affected coagulation parameters, including fibrinogen levels, the aPTT and PT, but not the hemoglobin concentration, white cell count, or platelet count. The
addition of anti-tissue factor antibodies to ancrod-treated rabbits had no additional effects on coagulation.
Assessment of glomerular injury
Kidney tissue was fixed in Bouin’s fixative, embedded
in paraffin, and 2 lm tissue sections were cut and stained
with periodic acid-Schiff (PAS) reagent. A minimum of
50 glomeruli was assessed to determine the crescent score
for each animal. The extent of crescent formation in each
glomerulus was scored semiquantitatively (0 to 3+) as
follows: 0, no crescent present; 1, crescent occupying up
to one third of Bowman’s space circumferentially; 2, cres-
cent occupying one third to two thirds of Bowman’s space;
and 3, crescent involving greater than two thirds of the
circumference of Bowmans space.
Plasma creatinine measurements were performed on
plasma samples using the alkaline picric acid method.
Proteinuria was calculated after collecting urine over the
final 24 hours of each experiment. Rabbits were housed
in metabolic cages with free access to fresh water and
standard chow. Residual bladder urine was aspirated af-
ter sacrifice. Protein concentrations were determined by
the Coomassie brilliant blue dye binding assay [26].
Assessment of glomerular fibrin deposition,
leukocyte recruitment, and MHC class II
For glomerular fibrin deposition, snap-frozen tissue
was embedded immediately in Optimal Cutting Temper-
ature Compound (Miles Scientific, Naperville, IL, USA)
and stored at −70◦C before 6 lm cryostat cut sections
were examined. Fibrin immunofluorescence staining was
performed on acetone fixed section (4◦C for 2 minutes)
followed by incubation with 10% normal goat or sheep
serum [5% phosphate-buffered saline (PBS) for 10 min-
utes, room temperature], then incubated with fluorescein
isothiocyanate (FITC)-conjugated sheep antirabbit fib-
rinogen (Research Plus, Bayonne, NJ, USA) (1:100) for
45 minutes. Slides were washed with PBS, mounted with
50% glycerol, and examined under a fluorescence micro-
scope (Leitz, Oberkochen, Germany). Glomerular fib-
rin deposition was assessed using a blinded protocol in
at least 50 glomeruli according to a previously published
protocol [9, 14, 21]. The degree of glomerular fibrin depo-
sition was scored semiquantitatively (0 to 3+) as follows:
0, no fibrin deposition; 1, fibrin occupying up to one third
of the glomerular cross-sectional area; 2, fibrin occupying
one third to two thirds of the glomerulus; and 3, greater
than two thirds of the glomerular cross-section covered
by fibrin.
For assessment of leukocytes and MHC class II, kidney
and spleen from each animal was fixed in periodate ly-
sine paraformaldehyde for 4 hours, washed (7% sucrose
in PBS), then frozen in liquid nitrogen-cooled isopen-
tane. Four micrometer sections were stained with either
Ken 5 (anti-CD5, a pan T-cell marker) [27], RAM 11
(macrophages) [28], or 2CAB12 (rabbit MHC class II
antigen) [29], followed by rabbit antimouse IgG globu-
lin (Dako, Glostrup, Denmark) (1:100), then horseradish
peroxidase and mouse antihorseradish peroxidase im-
munoglobulin (Dako) (1:100). Sections were incubated
with diaminobenzadine (Sigma), and counterstained with
Harris hematoxylin. Sections of spleen provided a pos-
itive control for each animal and either an irrelevant
isotype-matched monoclonal antibody or protein G-
purified mouse IgG was substituted for the specific mono-
clonal antibody to provide a negative control. Glomerular
leukocyte cell numbers were assessed using a blinded pro-
tocol. A minimum of 50 equatorially sectioned glomeruli
per animal were assessed per animal and the results were
expressed as cells per glomerular cross-section (c/gcs).
Expression of MHC class II in glomeruli was assessed
semiquantitatively in a blinded protocol by grading the
staining from 0 to +4 according to a previously published
protocol [30]. Glomeruli with no staining scored 0; 1, up
to 10% positive; 2, 10% to one third positive; 3, one third
to two thirds; and 4, greater than two thirds positive.
RESULTS
Defibrinogenation with ancrod prevents
pathologic glomerular fibrin deposition in
crescentic glomerulonephritis
Serum fibrinogen levels were 2.96 ± 0.39 lmol/L in un-
modified, control treated disease but were rarely within
the detectable range in the two ancrod-treated groups
(ancrod-treated alone 0.20 ± 0.13 lmol/L; ancrod and
anti-tissue factor-treated 0.16 ± 0.10 lmol/L) (Table 1). In
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Fig. 1. Glomerular fibrin deposition and glomerular crescent forma-
tion in control-treated rabbits with glomerulonephritis (GN), rabbits
with glomerulonephritis given ancrod alone, and rabbits given an-
crod and anti-tissue factor (TF) antibodies. (A) Significant and ex-
tensive glomerular fibrin deposition was observed in rabbits devel-
oping experimental crescentic anti-glomerular basement membrane
(GBM) glomerulonephritis. Ancrod treatment abrogated this patho-
logic glomerular fibrin deposition. (B) Associated with glomerular fib-
rin deposition extensive crescent formulation characterizes this model
of glomerulonephritis. This was significantly attenuated by ancrod-
induced defibrinogenation, although a minor component of crescent for-
mation was refractory to treatment. Combined ancrod and anti-tissue
factor antibody treatment abrogated glomerular crescent formation.
keeping with the degree of defibrinogenation, there was
no clot detected in either of the ancrod-treated groups. In
contrast, the aPTT in the control treated disease group
was 19.5 ± 1.4 seconds (normal, no glomerulonephritis
16.8 ± 1.8 seconds). The full blood examination was not
affected by ancrod or combined ancrod and anti-tissue
factor treatment. In particular, platelet counts were not
significantly different between the three groups of rabbits
with glomerulonephritis. Hemoglobin, total leukocyte
count, and circulating monocyte numbers were similarly
unaffected. Significant and extensive glomerular fibrin
deposition was observed in rabbits with given control
treatments [score (0 to 3+) 2.2 ± 0.2] (Fig. 1A), but
glomerular fibrin deposition was undetectable in defib-
rinogenated rabbits with glomerulonephritis (score 0 in
rabbits treated with ancrod alone, 0 in those treated with
ancrod and anti-tissue factor) (Fig. 1A), indicating com-
plete prevention of glomerular fibrin deposition by this
degree of ancrod-induced defibrinogenation.
Effects of defibrinogenation alone or with tissue
factor inhibition on renal injury
Frequent and severe crescent formation was seen in
control treated rabbits with glomerulonephritis [score (0
to 3+) 2.4 ± 0.5 in unmodified, control-treated glomeru-
lonephritis] (Figs. 1B and 2A and D). As expected,
crescent formation was markedly attenuated in rabbits
treated with ancrod alone (score 0.4 ± 0.4) (Figs. 1B
and 2B and E) and abrogated by the additional treat-
ment of anti-tissue factor antibodies with ancrod (score
0) (Figs. 1B and 2C and F). At the end of experiments
(day 4 post-disease induction), control-treated rabbits de-
veloped significant renal impairment (415 ± 51 lmol/L)
(Fig. 3A). The serum creatinine was 274 ± 37 lmol/L
in rabbits treated with ancrod alone (P = 0.02 control-
treated vs. ancrod-treated). This demonstrates that the
known preservation of glomerular filtration by ancrod-
induced defibrinogenation was reproduced in this ex-
periment. Additional treatment with anti-tissue factor
antibodies (as well as ancrod) further improved renal
function (serum creatinine 140 ± 19 lmol/L, P < 0.005
control-treated vs. ancrod-treated + anti-tissue factor
antibodies, P = 0.03 ancrod-treated vs. ancrod-treated
+ anti-tissue factor antibodies). Thus, although ancrod
treatment prevented glomerular fibrin deposition and
preserved glomerular filtration, inhibition of tissue fac-
tor in addition to defibrinogenation further protected
from loss of renal function. Twenty-four–hour urinary
protein excretion was 2.6 ± 0.4 g/day in control treated
disease (Fig. 3B), 5.6 ± 1.2 g/day in ancrod-treated, and
fell to 0.4 ± 0.2g/day in ancrod-treated and anti-tissue
factor–treated animals (P < 0.001 control-treated vs.
ancrod-treated, P < 0.001 control-treated vs. ancrod-
treated + anti-tissue factor antibodies, and P < 0.0001
ancrod-treated vs. ancrod-treated + anti-tissue factor
antibodies).
Effects of defibrinogenation with or without
anti-tissue factor antibodies on glomerular leukocyte
accumulation and MHC class II expression
The monoclonal antibody Ken 5 that detects CD5+
T cells revealed 6.4 ± 1.3 c/gcs in rabbits treated with
ancrod alone (Fig. 4A), 2.2 ± 0.7 c/gcs in those treated
with ancrod and anti-tissue factor, and 5.8 ± 1.8 c/gcs
in control-treated glomerulonephritis (P < 0.001 vs. ei-
ther the control-treated or ancrod-treated groups). RAM
11 antibody staining revealed a glomerular macrophage
count of 11.8 ± 2.8 c/gcs (Figs. 4B and 5A) in rabbits
with control-treated disease, 12.4 ± 3.0 c/gcs in ancrod-
treated rabbits (Fig. 5B), and 4.2 ± 1.9 c/gcs in rabbits
treated with both ancrod and anti-tissue factor antibod-
ies (P < 0.001 vs. either the control-treated or ancrod-
treated groups) (Fig. 5C). MHC class II expression,
determined by immunostaining with the monoclonal an-
tibody 2CAB12, was on average, moderate [score (0 to
4) 2.7 ± 0.2] (Fig. 5D and G) in control-treated glomeru-
lonephritis, reduced (2.1 ± 0.2) (Fig. 5E and G) in rabbits
treated with ancrod alone and further reduced to 1.6 ± 0.2
(Fig. 5F and G) in rabbits treated with ancrod and anti-
tissue factor (P < 0.005 for all group comparisons). While
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Fig. 2. Histologic injury in rabbits treated
with ancrod and ancrod + anti-tissue fac-
tor antibodies. Control-treated rabbits with
glomerulonephritis developed proliferative
glomerulonephritis (A) with severe glomeru-
lar injury (D). Ancrod treatment signifi-
cantly improved histologic appearances and
glomerular injury, but proliferative disease re-
mained (B and E). Combined ancrod and anti-
tissue factor antibody treatment resulted in
a further improvement in renal histology (C
and F) compared with ancrod alone [periodic
acid-Schiff (PAS) stained, original magnifica-
tion ×100 (A to C, low power views), ×200 (D
to F, high power views)].
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Fig. 3. Functional indices of renal disease in control treated rabbits
with glomerulonephritis (GN), rabbits with glomerulonephritis given
ancrod alone, and rabbits given ancrod and anti-tissue factor (TF) anti-
bodies. (A) Untreated rabbits developing crescentic glomerulonephritis
developed severe renal failure manifest by elevated creatinine levels.
Ancrod-induced defibrinogenation significantly attenuated renal fail-
ure and the addition of anti-tissue factor globulin afforded further sig-
nificant protection against renal failure. (B) Heavy proteinuria devel-
oped in untreated animals with crescentic glomerulonephritis that was
exacerbated by ancrod-induced defibrinogenation but significantly im-
proved by the addition of anti-tissue factor globulin treatment. Dot-
ted lines represent normal values. (A) ∗P = 0.02 vs. control glomeru-
lonephritis; ∗∗P < 0.005 vs. control glomerulonephritis, and P = 0.03 vs.
ancrod treatment alone. (B) ∗P < 0.001 vs. control glomerulonephritis;
∗∗P < 0.0001 vs. ancrod treatment alone.
much of the glomerular MHC class II expression localized
to areas staining for macrophages, MHC class II expres-
sion was seen in cells that did not stain positive for RAM
11, suggesting these cells were intrinsic glomerular cells.
DISCUSSION
This study demonstrates that tissue factor has a proin-
flammatory in vivo effect that is independent of fibrin for-
mation, thus linking the coagulation and inflammatory
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Fig. 4. Glomerular T cells (A) and macrophages (B) in control treated
rabbits with glomerulonephritis (GN), rabbits with glomerulonephritis
given ancrod alone and rabbits given ancrod and anti-tissue factor (TF)
antibodies. A significant glomerular influx of T cells, (CD5-positive),
and macrophages (RAM 11-positive) occurred in experimental crescen-
tic glomerulonephritis. This was unaffected by defibrinogenation with
ancrod but significantly affected by the administration of anti-tissue fac-
tor antibodies to ancrod-treated rabbits. ∗∗P < 0.001 vs. control-treated
glomerulonephritis or ancrod treatment alone.
pathways at the origin of in vivo coagulation. Not only
was renal injury prevented as manifest by the preserva-
tion of glomerular filtration (measured by serum creati-
nine), but proteinuria, MHC class II expression as well
as macrophage and T-cell infiltration were all decreased
by tissue factor inhibition in the absence of pathologic
glomerular fibrin deposition. The major effector cell to
control the nexus between the coagulation pathway and
inflammation is likely to be the macrophage given its
marked-up regulation of cell surface–anchored tissue fac-
tor during inflammation [10, 21]. In this study the de-
crease in inflammatory renal injury mediated by blockade
of the tissue factor factor VIIa interaction is shown here
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Fig. 5. Glomerular macrophage and major histocompatibility complex (MHC) class II expression in rabbits with glomerulonephritis (GN).
Glomerular macrophage accumulation (brown reaction product) was significant both control-treated rabbits (A) and rabbits given ancrod alone
(B), but significantly reduced in rabbits given ancrod and anti-tissue factor (TF) antibodies (C). Serial sections showing the same glomeruli showed
MHC class II expression (brown reaction product) was prominent in unmodified experimental crescentic glomerulonephritis (D). This was reduced
by defibrinogenation with ancrod (E) and further attenuated by the additional treatment with anti-tissue factor globulin (F). While much of the
MHC class II expression localized to areas of glomeruli with macrophage accumulation, some segmental areas of glomeruli (D and F, arrows)
showed MHC class II expression independent of macrophages. Semiquantitative analysis of MHC class II in glomeruli (G) showed a modest reduc-
tion with ancrod treatment and a more substantial reduction with ancrod and anti-tissue factor antibodies (serial sections, immunoperoxidase with
hematoxylin counterstain, original magnification ×200). ∗P < 0.005 vs. control glomerulonephritis; ∗∗P < 0.005 vs. both control glomerulonephritis
and ancrod treatment alone.
to correlate with a decrease in glomerular macrophage
infiltration and is independent of fibrin deposition.
Crescentic glomerulonephritis results from Th1 pre-
dominant nephritogenic immune response to antigens
in glomeruli [31]. Presentation of nephritogenic anti-
genic peptides by MHC class II expressing intrinsic
glomerular cells is required for the CD4 glomerular influx
that recruits and activates the major Th1 effector cells,
macrophages [32]. Fibrin deposition plays a relatively
minor role in regulation of MHC class II by nephritic
glomerular cells as expression was reduced in defibrino-
genated animals. However, glomerular leukocyte recruit-
ment was unaffected by defibrinogenation. Tissue factor
inhibition was associated with significant reduction in
MHC class II expression compared with defibrinogena-
tion and also a significant reduction in T-cell recruitment
was observed in rabbits treated with inhibitory anti-tissue
factor antibody as well as ancrod. This in turn was as-
sociated with a major reduction in macrophage influx.
Thus tissue factor and fibrin independently amplify MHC
expression. While defibrinogenation with ancrod alone
reduced glomerular MHC class II expression, this was
relatively minor compared with the greater reduction of
MHC class II expression in rabbits treated with both an-
crod and anti-tissue factor antibodies. This quantitative
difference is likely at least in part, to explain why an-
crod alone (unlike both ancrod and anti-tissue factor an-
tibodies together) did not diminish glomerular leukocyte
recruitment.
Rabbits were given ancrod prior to the initiation of
disease with anti-GBM serum. Treatment with ancrod
was shown to significantly inhibit glomerular fibrin de-
position with near complete systemic defibrinogenation
in both groups of rabbits receiving ancrod as measured
by abrogation of glomerular fibrin deposition, serum fib-
rinogen, the clot quality test of Reid, Chan, and Thean
[25] and the observation that the aPTT was unmeasur-
able in these rabbits. Clinically, this dose of ancrod was
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not associated with bleeding during the experimental
period nor was there evidence of unexpected hemor-
rhage at autopsy which is often found at higher doses of
ancrod.
Proteinuria was significantly increased in animals
treated with ancrod alone. This suggests that heavy fibrin
deposition in damaged glomeruli significantly diminished
glomerular filtration. Thus abolition of fibrin deposi-
tion enhances glomerular clearance rates, its known ben-
eficial effects on renal function (glomerular filtration)
confirmed by the significant fall in serum creatinine in
ancrod-treated compared with control-treated rabbits
with glomerulonephritis. This is consistent with other re-
ports of improved glomerular filtration rates with ancrod
treatment of experimental crescentic glomerulonephri-
tis [6, 8]. Interestingly, the augmentation of proteinuria
seen in animals treated with ancrod treatment alone is
abolished by the additional treatment with anti-tissue
factor in these fully defibrinogenated animals. Further-
more, this value is significantly less than that of animals
with either control-treated disease or ancrod treatment.
This strongly suggests that in crescentic glomerulonephri-
tis, tissue factor in addition to its role in initiating
pathologic coagulation is augmenting inflammation by
facilitating the expression of MHC class II and direct-
ing injurious delayed-type hypersensitvity responses to
glomeruli. Ancrod administration has previously been
shown to ameliorate disease in this model of glomeru-
lonephritis when used from the initiation of disease [6–9]
and as treatment early in the disease [8]. Despite ancrod
treatment, decline in renal function still occurs and is as-
sociated with the development of massive proteinuria and
infiltration of macrophages is unaffected [4]. These stud-
ies have suggested that amelioration of the coagulation-
dependent impairment in glomerular filtration rate
with unmodified inflammatory damage (manifested
histologically as mesangial proliferation and cellular
infiltration) allows delivery of more protein to immune-
injured glomeruli resulting in increased proteinuria. In
our studies, ancrod-treated animals had increased pro-
teinuria with no decrease in the number of glomerular
T cells and macrophages, further supporting this hypoth-
esis suggesting that defibrinogenation was protective of
renal function through its anticoagulant role. The cur-
rent observations are supported by studies in murine
anti-GBM glomerulonephritis using fibrinogen-deficient
mice [33]. In these studies, proteinuria was enhanced
in fibrinogen-deficient mice with glomerulonephritis in
the presence of reduced glomerular fibrin deposition and
lower serum creatinine values compared with genetically
normal mice with glomerulonephritis [33]. However, in
the skin, the deposition of fibrin is important in stable
wound healing [34]. Despite the different structure and
functions of the dermis and the glomerulus, it is possible
that in some circumstances fibrin deposition in glomeruli
may play a similar role in providing an initial matrix for
subsequent repair [35]. The absence of fibrin in glomeruli
coupled with persisting inflammation in rabbits treated
with ancrod alone may have contributed to the increased
proteinuria in these animals, compared with fibrin intact
rabbits.
In the current studies, there was an additional compo-
nent of protection from deterioration in renal function
seen with the addition of tissue factor inhibition suggest-
ing a fibrin independent, delayed-type hypersensitivity–
mediated, contribution to the loss of function in this
condition. These dual injurious functions of tissue fac-
tor were initially suggested by studies of in vivo blockage
of the tissue factor/factor VII interaction with anti-tissue
factor antibody in coagulation intact rabbits given anti-
GBM antibody. This treatment resulted in decreased
proteinuria and MHC class II expression compared to
control-treated disease [14]. In addition, infusion of TFPI
(forming an inactive quaternary complex of tissue fac-
tor/factors VIIa and Xa) [12] resulted in not only de-
creased coagulation and fibrin formation but also in less
inflammation in both lipopolysaccharide-induced septic
shock models [36] and experimental glomerulonephri-
tis [15]. Tissue factor has been shown to be significantly
up-regulated on endothelial cells and macrophages in hu-
man and experimental glomerulonephritis. In vivo injec-
tion of anti-tissue factor antibodies reduced peritoneal
macrophage activation (assessed by reduced reactive
oxygen species production and MHC class II expression)
[13]. In vitro, human monocyte derived macrophages had
factor VIIa augmented triggered reactive oxygen species
production and intracellular calcium flux suggesting tis-
sue factor–mediated macrophage activation and intracel-
lular signaling [13].
Precedence exists for the dual proinflammatory and
procoagulant roles of coagulation proteases binding to
their cell surface receptors. Both the thrombin receptor
protease-activated receptor-1 (PAR-1) [37] and endothe-
lial protease receptor-1 (EPR-1) [38, 39], the cell-surface
receptor for factor Xa, are constitutively expressed on
T cells, macrophages, and endothelial cells. In vitro bind-
ing of the protease to its receptor can cause calcium
signals and proliferation. In vivo experiments have
demonstrated that thrombin receptor–deficient mice,
with normal coagulation, are protected from the develop-
ment of crescentic glomerulonephritis [19] and blocking
the EPR-1 factor Xa interaction prevented murine graft
versus host disease [40].
CONCLUSION
These studies establish a dual procoagulant and inde-
pendent proinflammatory function induced by tissue fac-
tor factor VIIa binding in an in vivo model of crescentic
654 Cunningham et al: Tissue factor and glomerular inflammation
glomerulonephritis clearly related to crescentic glomeru-
lonephritis in humans.
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